Shandong Weigao Group Medical Polymer Company Limited

SEHK:1066 Rapporto sulle azioni

Cap. di mercato: HK$21.0b

Shandong Weigao Group Medical Polymer Crescita futura

Future criteri di controllo 1/6

Shandong Weigao Group Medical Polymer prevede che gli utili e i ricavi cresceranno rispettivamente di 10.1% e 7.1% all'anno. Si prevede che l'EPS crescerà di 10% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 9.2% in 3 anni.

Informazioni chiave

10.1%

Tasso di crescita degli utili

10.0%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili41.0%
Tasso di crescita dei ricavi7.1%
Rendimento futuro del capitale proprio9.2%
Copertura analitica

Good

Ultimo aggiornamento27 Dec 2024

Aggiornamenti recenti sulla crescita futura

Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Sep 24
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Aug 30
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Mar 28
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Recent updates

Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Nov 26
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Nov 04
Be Wary Of Shandong Weigao Group Medical Polymer (HKG:1066) And Its Returns On Capital

Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Sep 24
Analysts Have Been Trimming Their Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Price Target After Its Latest Report

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Aug 30
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Just Reported, And Analysts Assigned A HK$6.74 Price Target

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Jun 25
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 27% Share Price Plunge Could Signal Some Risk

Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Jun 23
Here's What To Make Of Shandong Weigao Group Medical Polymer's (HKG:1066) Decelerating Rates Of Return

Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

May 31
Shandong Weigao Group Medical Polymer's (HKG:1066) Shareholders Will Receive A Bigger Dividend Than Last Year

We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

May 22
We Think Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) CEO Compensation Package Needs To Be Put Under A Microscope

Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Apr 23
Earnings Not Telling The Story For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Mar 28
Analysts Have Lowered Expectations For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) After Its Latest Results

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Jan 09
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Shares May Have Run Too Fast Too Soon

Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Dec 22
Returns On Capital Are Showing Encouraging Signs At Shandong Weigao Group Medical Polymer (HKG:1066)

Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Nov 10
Are Investors Undervaluing Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) By 44%?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Oct 05
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Aug 01
Return Trends At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Appealing

Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Jul 19
Is Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Trading At A 28% Discount?

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Jun 22
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

Jun 09
Is Shandong Weigao Group Medical Polymer (HKG:1066) Using Too Much Debt?

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Apr 27
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

Mar 17
Shandong Weigao Group Medical Polymer (HKG:1066) Ticks All The Boxes When It Comes To Earnings Growth

A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Feb 27
A Look At The Intrinsic Value Of Shandong Weigao Group Medical Polymer Company Limited (HKG:1066)

Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Jan 18
Returns On Capital At Shandong Weigao Group Medical Polymer (HKG:1066) Have Hit The Brakes

Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Dec 12
Does Shandong Weigao Group Medical Polymer (HKG:1066) Have A Healthy Balance Sheet?

Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Nov 29
Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Shares Could Be 21% Below Their Intrinsic Value Estimate

Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Nov 14
Here's Why We Think Shandong Weigao Group Medical Polymer (HKG:1066) Might Deserve Your Attention Today

Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

Oct 03
Shandong Weigao Group Medical Polymer (HKG:1066) Is Paying Out A Larger Dividend Than Last Year

The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Sep 21
The Returns At Shandong Weigao Group Medical Polymer (HKG:1066) Aren't Growing

Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Sep 05
Shandong Weigao Group Medical Polymer (HKG:1066) Could Easily Take On More Debt

Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Aug 23
Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) Intrinsic Value Is Potentially 27% Above Its Share Price

Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

Aug 08
Here's Why Shandong Weigao Group Medical Polymer (HKG:1066) Has Caught The Eye Of Investors

There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Jun 22
There's Been No Shortage Of Growth Recently For Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital

Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

Jun 08
Shandong Weigao Group Medical Polymer (HKG:1066) Will Pay A Smaller Dividend Than Last Year

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

May 16
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 27% Undervalued

Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

May 03
Is Shandong Weigao Group Medical Polymer (HKG:1066) A Risky Investment?

Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher

Mar 17
Shandong Weigao Group Medical Polymer's (HKG:1066) Returns On Capital Are Heading Higher

Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?

Jan 28
Is There An Opportunity With Shandong Weigao Group Medical Polymer Company Limited's (HKG:1066) 42% Undervaluation?

Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

Jan 13
Does Shandong Weigao Group Medical Polymer (HKG:1066) Deserve A Spot On Your Watchlist?

Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Dec 17
Returns Are Gaining Momentum At Shandong Weigao Group Medical Polymer (HKG:1066)

Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

Dec 05
Shandong Weigao Group Medical Polymer (HKG:1066) Seems To Use Debt Rather Sparingly

An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

Oct 18
An Intrinsic Calculation For Shandong Weigao Group Medical Polymer Company Limited (HKG:1066) Suggests It's 32% Undervalued

Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?

Oct 06
Do Shandong Weigao Group Medical Polymer's (HKG:1066) Earnings Warrant Your Attention?

Previsioni di crescita degli utili e dei ricavi

SEHK:1066 - Stime future degli analisti e dati finanziari passati (CNY Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202615,5852,5012,2013,5766
12/31/202514,7312,3191,9623,0137
12/31/202413,8192,1352,0862,7167
6/30/202412,9671,9122,0182,704N/A
3/31/202413,0981,9572,0662,751N/A
12/31/202313,2292,0022,1132,799N/A
9/30/202313,3982,2211,6392,539N/A
6/30/202313,5662,4401,1662,280N/A
3/31/202313,6572,6021,1732,287N/A
12/31/202213,7472,7641,1812,295N/A
9/30/202213,9032,6761,4332,573N/A
6/30/202214,0582,5891,6852,852N/A
3/31/202213,6332,4321,8032,969N/A
12/31/202113,2092,2761,9203,087N/A
9/30/202112,9232,2882,0213,088N/A
6/30/202112,6362,3002,1213,089N/A
3/31/202112,1292,1941,9712,938N/A
12/31/202011,6222,0871,8212,788N/A
9/30/202011,1391,9981,5572,533N/A
6/30/202010,6561,9091,2922,277N/A
3/31/202010,5201,8791,3152,300N/A
12/31/201910,3841,8501,3372,322N/A
9/30/20199,9931,8051,4562,347N/A
6/30/20199,6021,7601,5752,371N/A
3/31/20199,2051,6161,5002,295N/A
12/31/20188,8091,4731,4242,219N/A
6/30/20187,4651,2553831,812N/A
3/31/20186,8791,255N/A1,539N/A
12/31/20176,2931,255N/A1,266N/A
6/30/20175,4021,297N/A1,233N/A
3/31/20175,5111,165N/A1,143N/A
12/31/20165,6201,033N/A1,053N/A
9/30/20166,4841,010N/A1,042N/A
6/30/20166,237914N/A1,030N/A
3/31/20166,0781,013N/A1,041N/A
12/31/20155,9191,113N/A1,053N/A
9/30/20155,8781,237N/AN/AN/A
6/30/20155,6101,196N/A622N/A
3/31/20155,5481,161N/AN/AN/A
12/31/20145,2781,085N/A711N/A
9/30/20145,011307N/AN/AN/A
6/30/20144,996431N/A794N/A
3/31/20144,769376N/AN/AN/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 1066 ( 10.1% all'anno) è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Si prevede che gli utili di 1066 ( 10.1% all'anno) cresceranno più lentamente rispetto al mercato Hong Kong ( 11.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 1066 cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 1066 ( 7.1% all'anno) crescerà più lentamente rispetto al mercato Hong Kong ( 7.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 1066 ( 7.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di 1066 sarà basso tra 3 anni ( 9.2 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2025/01/02 15:53
Prezzo dell'azione a fine giornata2025/01/02 00:00
Guadagni2024/06/30
Guadagni annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Shandong Weigao Group Medical Polymer Company Limited è coperta da 35 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jason MannBarclays
Derrick SunBNP Paribas Securities (Asia)
Feng Qiang SunBOCOM International Securities Limited